港股異動 | 控股股東收購股權持續發酵 復鋭醫療科技三連升累漲17%
格隆匯10月4日丨復鋭醫療科技(1696.HK)繼前兩交易日分別上漲4.17%、5.65%後,於今日再度上漲6.24%,三連升累計上漲17%,現報0.28港元,盤中最高見4.84港元創自5月6日以來新高,暫成交190.46萬港元,最新總市值21.09億港元。公司在9月30日發佈公告稱,控股股東復星醫藥之全資附屬公司暨公司主要股東能悦擬從Magnificent View收購9697.6萬股公司股份。完成後,復星醫藥通過附屬持有3.3055億股公司股份,持股比例由52.83%升至74.76%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.